Trump's threat to impose 100-200% tariffs on generic drugs aims to reshore production in the US. This directly impacts India, which exports $9.7 billion worth of pharmaceuticals to the US annually, with 90% being generics. Indian pharma companies are responding by increasing US investments and acquisitions to secure market access.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Tariff Threat: 100% after 2 years, 200% thereafter
- ›India's Pharma Exports to US (2025): $9.7 billion
- ›Target this Data: India's pharma exports to US in 2025: $9.7 billion
- ›Target this Nodal Body: USFDA (approves manufacturing facilities of Indian companies in US)
- ›Target this Legal Point: Section 232 of Trade Expansion Act 1962 (used for tariff threat)
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.